NASDAQ: MNPRMonopar Therapeutics Earnings Dates, Reports, Calls
Monopar Therapeutics earnings were -$15.0M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest MNPR earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$3.9M, down 25.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MNPR reported annual earnings of -$13.7M, with -12% growth.
MNPR earnings history
Current Revenue
$0.0
Current Earnings
-$15.0M
Current Profit Margin
0%
MNPR Return on Equity
Current Company
-12.8%
Current Industry
-142%
Current Market
13.5%
MNPR's Return on Equity (-12.8%)... subscribe to Premium to read more.
High Return on Equity Performance
MNPR Return on Assets
Current Company
-12.6%
Current Industry
-13.7%
MNPR is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance
Be the first to know when MNPR announces earnings.
MNPR Return on Capital Employed
Current Company
-11.06%
Current Industry
-9.5%
MNPR has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance
MNPR vs Biotech Stocks
Monopar Therapeutics Earnings Reports & History FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.